News | Stent Grafts | May 04, 2022

Reshaping the Future of Cardiac Bypass Surgery With Biocompatible Graft

Medical 21 Files Regulation A+ Offering, accepting invitations for $40 million funding round offering

Artificial graft

Medical 21's artificial graft technology


May 4, 2022 – Seeking to bolster its development of a biocompatible graft that promises to reshape the future of cardiac bypass surgery, Medical 21, a medtech device company, recently announced it has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC) and is now accepting, from the public, reservations for its $40 million funding round on its website.

Medical 21’s innovative artificial graft eliminates the need of harvesting saphenous vein grafts (SVGs) or other veins and arteries, shortens procedure time, reduces pain, decreases patient recovery time, and avoids scarring, among many other benefits.

Medical 21’s graft technology will not only vastly improve the recovery of heart bypass patients but also assists cardiac surgeons by reducing operating times. The graft provides the flexibility to perform bypass surgery either on the heart-lung bypass machine or “off-pump” and reduces costs associated with wound-related post-operative care and readmissions.

Manny Villafana

Medical 21 was founded by Manny Villafaña, Ph.D. Sc.D., a globally recognized entrepreneur and medical device developer. Known as the co-developer of the St. Jude heart valve and founder of St. Jude Medical, Inc., Villafaña has been named a Living Legend of Medicine by The World Society of CardioThoracic Surgery and is an award-winning USA Master Entrepreneur, a member of the Minnesota Business Hall of Fame, an inductee of the Minnesota Science and Technology Hall of Fame, and recipient of the Medical Design Association Lifetime Achievement Award. Villafaña has led seven of his companies into successful IPOs.

“We see Reg A+ financing as the 21st century way of funding a company and bringing this life-changing solution to market,” said Villafaña. “Despite having an accomplished career in the cardiac health space, Medical 21 is by far the company I’m most excited about because of its enormous potential to improve conditions for the millions of coronary artery heart bypass surgery patients.”

For more information: https://medical21.com/


Related Content

News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
News | Cardiovascular Surgery

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
News | Cardiovascular Surgery

October 18, 2023 — A study published in The Annals of Thoracic Surgery demonstrates outstanding long-term survival ...

Home October 18, 2023
Home
Subscribe Now